Theravance, Inc. Abandons ADHD Drug After Drug Fails Phase 2 Study
Published: Nov 15, 2013
Today Rick E Winningham, Chief Executive Officer of Theravance, Inc. (Nasdaq: THRX) presented at the 2013 Credit Suisse Annual Health Care Conference in Scottsdale, Arizona. During the slide presentation, Mr. Winningham announced that TD-9855 did not meet the primary efficacy endpoint of symptom reduction as measured by AISRS (Adult Investigator Symptom Rating Scale) total score versus placebo in the Phase 2 study in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD). TD 9855 was generally well tolerated with no serious adverse events at either the 5 mg or 20 mg dose of TD-9855.
Help employers find you! Check out all the jobs and post your resume.